SG11202103118PA - Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof - Google Patents
Crystal form of morpholino quinazoline compound, preparation method therefor and use thereofInfo
- Publication number
- SG11202103118PA SG11202103118PA SG11202103118PA SG11202103118PA SG11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA SG 11202103118P A SG11202103118P A SG 11202103118PA
- Authority
- SG
- Singapore
- Prior art keywords
- preparation
- crystal form
- method therefor
- quinazoline compound
- morpholino quinazoline
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201811131702 | 2018-09-27 | ||
| PCT/CN2019/105688 WO2020063368A1 (zh) | 2018-09-27 | 2019-09-12 | 吗啉基喹唑啉类化合物的晶型、其制备方法及应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11202103118PA true SG11202103118PA (en) | 2021-04-29 |
Family
ID=69953307
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202103118PA SG11202103118PA (en) | 2018-09-27 | 2019-09-12 | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11168072B2 (de) |
| EP (1) | EP3858830B1 (de) |
| JP (1) | JP7071588B2 (de) |
| KR (1) | KR20210069664A (de) |
| CN (1) | CN110950844B (de) |
| AU (1) | AU2019345706B2 (de) |
| BR (1) | BR112021006026A2 (de) |
| CA (1) | CA3114260A1 (de) |
| EA (1) | EA202190880A1 (de) |
| MX (1) | MX2021003576A (de) |
| SG (1) | SG11202103118PA (de) |
| TW (1) | TWI820223B (de) |
| WO (1) | WO2020063368A1 (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3858830B1 (de) | 2018-09-27 | 2022-11-16 | Shanghai Yingli Pharmaceutical Co. Ltd. | Kristallform der morpholino-chinazolinverbindung, verfahren zu ihrer herstellung und ihre verwendung |
| CN115120732A (zh) * | 2021-03-26 | 2022-09-30 | 上海璎黎药业有限公司 | 一种喹唑啉化合物的药物组合物及其制备方法 |
| CN115252620A (zh) * | 2021-04-30 | 2022-11-01 | 上海璎黎药业有限公司 | 一种喹唑啉化合物及药物组合物的应用 |
| CN118139626A (zh) * | 2021-09-01 | 2024-06-04 | 江苏恒瑞医药股份有限公司 | 一种pi3k抑制剂与btk抑制剂在制备治疗淋巴瘤的药物中的用途 |
| CN118525011A (zh) * | 2022-08-24 | 2024-08-20 | 上海璎黎药业有限公司 | 一种吗啉基喹唑啉类化合物、其制备方法及应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101701109B1 (ko) | 2007-10-05 | 2017-02-13 | 베라스템, 인코포레이티드 | 피리미딘 치환된 퓨린 유도체 |
| EP2279188B1 (de) | 2008-05-30 | 2015-01-28 | Genentech, Inc. | Purin-pi3k-hemmerverbindungen und anwendungsverfahren dafür |
| CN106831721B (zh) | 2013-10-16 | 2019-10-22 | 上海璎黎药业有限公司 | 稠合杂环化合物、其制备方法、药物组合物和用途 |
| SG11201610341PA (en) * | 2014-06-24 | 2017-01-27 | Gilead Sciences Inc | Phosphatidylinositol 3-kinase inhibitors |
| US10689359B2 (en) * | 2015-12-25 | 2020-06-23 | Xuanzhu Pharma Co., Ltd. | Crystals of quinazoline derivative and preparation method therefor |
| EP3858830B1 (de) | 2018-09-27 | 2022-11-16 | Shanghai Yingli Pharmaceutical Co. Ltd. | Kristallform der morpholino-chinazolinverbindung, verfahren zu ihrer herstellung und ihre verwendung |
-
2019
- 2019-09-12 EP EP19864074.0A patent/EP3858830B1/de active Active
- 2019-09-12 SG SG11202103118PA patent/SG11202103118PA/en unknown
- 2019-09-12 US US17/279,185 patent/US11168072B2/en active Active
- 2019-09-12 AU AU2019345706A patent/AU2019345706B2/en active Active
- 2019-09-12 EA EA202190880A patent/EA202190880A1/ru unknown
- 2019-09-12 CN CN201910861902.7A patent/CN110950844B/zh active Active
- 2019-09-12 CA CA3114260A patent/CA3114260A1/en active Pending
- 2019-09-12 WO PCT/CN2019/105688 patent/WO2020063368A1/zh unknown
- 2019-09-12 MX MX2021003576A patent/MX2021003576A/es unknown
- 2019-09-12 BR BR112021006026-0A patent/BR112021006026A2/pt unknown
- 2019-09-12 JP JP2021516990A patent/JP7071588B2/ja active Active
- 2019-09-12 KR KR1020217012398A patent/KR20210069664A/ko active Pending
- 2019-09-27 TW TW108135116A patent/TWI820223B/zh active
Also Published As
| Publication number | Publication date |
|---|---|
| US20210317104A1 (en) | 2021-10-14 |
| WO2020063368A1 (zh) | 2020-04-02 |
| AU2019345706A1 (en) | 2021-05-27 |
| EA202190880A1 (ru) | 2021-06-28 |
| TW202024066A (zh) | 2020-07-01 |
| TWI820223B (zh) | 2023-11-01 |
| JP2021528487A (ja) | 2021-10-21 |
| KR20210069664A (ko) | 2021-06-11 |
| MX2021003576A (es) | 2021-05-28 |
| AU2019345706B2 (en) | 2024-02-22 |
| CA3114260A1 (en) | 2020-04-02 |
| US11168072B2 (en) | 2021-11-09 |
| CN110950844B (zh) | 2024-01-30 |
| BR112021006026A2 (pt) | 2021-06-29 |
| EP3858830B1 (de) | 2022-11-16 |
| CN110950844A (zh) | 2020-04-03 |
| EP3858830A1 (de) | 2021-08-04 |
| EP3858830A4 (de) | 2021-09-15 |
| JP7071588B2 (ja) | 2022-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11202103118PA (en) | Crystal form of morpholino quinazoline compound, preparation method therefor and use thereof | |
| ZA202001447B (en) | M-diamide compound and preparation method therefor and use thereof | |
| HK1248231A1 (zh) | 取代的喹唑啉化合物和其使用方法 | |
| EP3246328A4 (de) | Heterocyclische chinazolinverbindung als egfr-kinase-inhibitoren sowie herstellung und anwendung davon | |
| EP3508481A4 (de) | Kristalline form von ozanimodhydrochlorid und herstellungsverfahren dafür | |
| EP3812378A4 (de) | Kristalline form von arn-509, herstellungsverfahren dafür und verwendung davon | |
| EP3269719A4 (de) | Kristalline form des jak-hemmers und herstellungsverfahren dafür | |
| EP3269711A4 (de) | Solvatfreie stabile apremilast-kristallform ii und herstellungsverfahren dafür | |
| EP3312151A4 (de) | Oxidationsinduzierte selbstheilende keramikzusammensetzung mit heilungsaktivator, verfahren zur herstellung davon, verwendung davon und verfahren zur verbesserung der funktionalität einer oxidationsinduzierten selbstheilenden keramikzusammensetzung | |
| HK1256860A1 (zh) | 喹唑啉衍生物的晶體及其製備方法 | |
| EP3597656A4 (de) | Steviosid-m-kristallform, herstellungsverfahren dafür und verwendung davon | |
| EP3502100A4 (de) | Kristallformen von ozanimod und herstellungsverfahren dafür | |
| PT3495352T (pt) | Formas de cristal de um antagonista de recetor de androgénio, método de preparação e utilização das mesmas | |
| EP3530650A4 (de) | Kristalline form von (r)-4-hydroxy-2-oxo-1-pyrrolidinacetamid, herstellungsverfahren dafür und verwendung davon | |
| EP3369733A4 (de) | Kristallform von 4h-pyrazolo[1,5-a]benzimidazol-verbindung, herstellungsverfahren dafür und zwischenprodukt davon | |
| SG11202103772WA (en) | Fluorescent diamond and method for producing same | |
| EP3330267A4 (de) | Salz eines chinazolinderivats oder eines kristalls davon und verfahren zur herstellung eines salzes eines chinazolinderivats oder eines kristalls daraus | |
| EP3805229A4 (de) | Salz einer kondensierten ringpyrimidinverbindung, ihre kristallform und verfahren zu ihrer herstellung und ihre verwendung | |
| EP3795153A4 (de) | Hc-1119-formulierung, herstellungsverfahren und verwendung davon | |
| HK1252375A1 (zh) | 喹唑啉衍生物的晶體及其製備方法 | |
| SG11202110055SA (en) | Crystal form of phosphodiesterase inhibitor, preparation method therefor and use thereof | |
| EP3967690A4 (de) | Pyrrolamidopyridonverbindung, herstellungsverfahren dafür und verwendung davon | |
| IL263868A (en) | Crystal structures of aminomethyl-converted tetracyclines and processes for their preparation | |
| EP3736273A4 (de) | Neue kristallform von acalabrutinib und herstellungsverfahren und verwendung davon | |
| HK1258757A1 (zh) | 4H-吡唑並[1，5-α]苯並咪唑類化合物的鹽型、晶型及其製備方法和中間體 |